论文部分内容阅读
目的探讨CD117在急性髓系白血病病程中表达及其临床意义。方法应用CD45/SSC设门,直接荧光标记法,经流式细胞术对122例不同病程急性髓系白血病(AML)和47例急性淋巴细胞白血病(ALL)进行CD117的检测。结果对照组、ALL及AML3组CD117的表达阳性率和表达率差异有统计学意义(χ2=41.681,F=35.753,P﹤0.01)。AML组CD117的表达阳性率(58.9%)及表达率[(29.4±19.7)%]均明显高于对照组[(0,(4.2±1.2)%)]及ALL组(8.5%,8.9%±6.3%);在AML中,初治病例、CR病例及复发病例CD117的阳性率分别为58.9%、6.5%、72.2%,表达率分别为(29.4±19.7)%、(11.5±7.9)%、(34.2±20.1)%。3组间CD117的阳性率及表达率差异均有统计学意义(χ2=28.103,F=14.864,P﹤0.01)。CR组的CD117阳性率及表达率均明显低于初治组和复发组。结论 CD117阳性表达可作为AL髓系免疫表型依据;单独或联合其他抗体检测AML患者骨髓中CD117的表达可以作为预测复发及监测MRD的指标之一。
Objective To investigate the expression of CD117 in the course of acute myeloid leukemia and its clinical significance. Methods CD45 / SSC was used to detect CD117 in 122 cases of acute myeloid leukemia (AML) and 47 cases of acute lymphoblastic leukemia (ALL) by flow cytometry with direct fluorescent labeling. Results The positive rate and the expression rate of CD117 in the control group, ALL and AML3 groups were significantly different (χ2 = 41.681, F = 35.753, P <0.01). The positive expression rate of CD117 in AML group (58.9%) and the expression rate (29.4 ± 19.7%) were significantly higher than those in control group [(0, 4.2 ± 1.2)%] and ALL group (8.5%, 8.9% ± 6.3%). The positive rates of CD117 in newly diagnosed cases, CR cases and recurrent cases were 58.9%, 6.5% and 72.2% respectively in AML, the positive rates were (29.4 ± 19.7)% and (11.5 ± 7.9)%, (34.2 ± 20.1)%. The positive rate and the expression rate of CD117 between the three groups were statistically significant (χ2 = 28.103, F = 14.864, P <0.01). The positive rate and the expression rate of CD117 in CR group were significantly lower than those in initial treatment group and recurrence group. Conclusion The positive expression of CD117 can be used as the basis of AL myeloid immunophenotype. The detection of CD117 in the bone marrow of AML patients alone or in combination with other antibodies can be used as one of the predictors of relapse and MRD.